Full coverage· Economy· Updated
New Med Seeks Approval for CEO's $27,000 Monthly Salary and Stock Options
New Med, controlled by Yitzhak Tshuva, is seeking shareholder approval for CEO Yanki Kuint's compensation package, which includes a NIS 100,000 monthly salary for a 70% role and NIS 3 million in stock options. This exceeds the company's stated compensation policy. The company cited Kuint's qualifications for the role.
2 newsrooms · 1 language · since
Plus
What happened
- 01New Med seeks approval for CEO Yanki Kuint's NIS 100,000 monthly salary and NIS 3 million stock options.
- 02Kuint's proposed salary exceeds New Med's established compensation policy for a 70% role.
- 03The company cited Kuint's qualifications as essential for addressing regulatory challenges.
- 04Former acting CEO Niv Serena will receive NIS 3 million annually plus stock options.
- 05New Med is controlled by businessman Yitzhak Tshuva.
Former acting CEO Niv Serena will receive NIS 3 million annually plus stock options.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- Centre1
- RightNone
- HarediNone
- ArabNone
- Other1
How it broke
See which of the 2 newsrooms broke it, and who waited